Achilles Therapeutics Pl-adr logo

Achilles Therapeutics Pl-adr Share Price Today (NASDAQ: ACHL)

Achilles Therapeutics Pl-adr share price is $0 & ₹0.00 as on 19 Mar 2025 IST

▲

-1.48

(-100%)

Market is closed - opens 7 PM, 18 Jul 2025

Bell Icon

The stock has been delisted from the stock exchange on 20 Mar 2025

View live Achilles Therapeutics Pl-adr share price in Dollar and Rupees. Guide to invest in Achilles Therapeutics Pl-adr stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Achilles Therapeutics Pl-adr, along with analyst recommendations, forecasts, and comprehensive financials.

Achilles Therapeutics Pl-adr (ACHL) Key Statistics

in dollars & INR

Previous Close
$1.48
Open
$1.48
Market Capitalization
$63.2M
Today's Volume
$1.2M
Revenue TTM
$0.0
EBITDA
$-67.2M
Earnings Per Share (EPS)
$-1.66
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-52.12%

How to invest in Achilles Therapeutics Pl-adr Stock (ACHL) from India?

It is very easy for Indian residents to invest directly in Achilles Therapeutics Pl-adr from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Achilles Therapeutics Pl-adr stock in both Indian Rupees (INR) and US Dollars (USD). Search for Achilles Therapeutics Pl-adr or ACHL on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Achilles Therapeutics Pl-adr or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Achilles Therapeutics Pl-adr shares which would translate to null fractional shares of Achilles Therapeutics Pl-adr as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Achilles Therapeutics Pl-adr, in just a few clicks!

Global Institutional Holdings in Achilles Therapeutics Pl-adr

  • Syncona Portfolio Ltd.

    26.98%

  • BML Capital Management LLC

    9.98%

  • FCPM III SERVICES BV

    5.82%

  • Redmile Group, LLC

    3.91%

  • Vestal Point Capital LP

    3.65%

  • Ikarian Capital, LLC

    3.51%

Analyst Recommendation on Achilles Therapeutics Pl-adr

Rating
Trend

Buy

    70%Buy

    20%Hold

    10%Sell

Based on 10 Wall street analysts offering stock ratings for Achilles Therapeutics Pl-adr(by analysts ranked 0 to 5 stars)

About Achilles Therapeutics Pl-adr

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Organization
Achilles Therapeutics Pl-adr
Employees
204
CEO
Dr. Iraj Ali Ph.D.
Industry
Miscellaneous

Management People of Achilles Therapeutics Pl-adr

NameTitle
Dr. Iraj Ali Ph.D.
CEO & Director
Dr. Sergio A. Quezada Ph.D.
Founder
Mr. Robert Coutts
Chief Financial Officer
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Charles Swanton FMEDSCI, M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Mr. Lee M. Stern
Vice President of Investor Relations & External Communications
Mr. Daniel Carey Cazel Hood
General Counsel & Company Secretary
Julia Wilson
Head of Communications
Mr. Tariq Ahmed
Executive Vice President of People

Important FAQs about investing in ACHL Stock from India :

Can Indians buy Achilles Therapeutics Pl-adr shares?

Yes, Indians can invest in the Achilles Therapeutics Pl-adr (ACHL) from India.

With INDmoney, you can buy Achilles Therapeutics Pl-adr at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Achilles Therapeutics Pl-adr at zero transaction cost.

How can I buy Achilles Therapeutics Pl-adr shares from India?

It is very easy to buy Achilles Therapeutics Pl-adr from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Achilles Therapeutics Pl-adr (ACHL) be purchased?

Yes, you can buy fractional shares of Achilles Therapeutics Pl-adr with INDmoney app.

What are the documents required to start investing in Achilles Therapeutics Pl-adr stocks?

To start investing in Achilles Therapeutics Pl-adr, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Achilles Therapeutics Pl-adr?

Today's market capitalisation of Achilles Therapeutics Pl-adr ACHL is 63.2M

Who is the Chief Executive Officer (CEO) of Achilles Therapeutics Pl-adr ?

Dr. Iraj Ali Ph.D. is the current Chief Executive Officer (CEO) of Achilles Therapeutics Pl-adr.